Back to Directory Sharon Appelbaum Nachman Email sharon.nachman@stonybrook.edu Institution SUNY Health Science Center at Stony Brook Title Investigator Request an Update Affiliated Studies IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling P1065: Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Youth (Versions 1.0 - 3.0) and Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth (Version 4.0) DAIDS Number 10396 Research Area Other Study Status Concluded P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up P1004s: Intensive PK substudies in ACTG 403 DAIDS Number 10313 Research Area Other Study Status Concluded P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded Show All
IMPAACT 2036: Phase I/II Study of the Safety, Tolerability, Acceptability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living with HIV-1, Two to Less Than 12 Years of Age DAIDS Number 38932 Research Area Therapeutics Study Status Enrolling
P1065: Phase I/II Study of Safety and Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in HIV-Infected Youth (Versions 1.0 - 3.0) and Open Label Immunogenicity Study of a Booster Dose of MCV4 in Previously Immunized HIV-Infected Children and Youth (Version 4.0) DAIDS Number 10396 Research Area Other Study Status Concluded
P1113: AERAS-404 TB Vaccine in BCG-Primed Infants DAIDS Number 11911 Research Area Tuberculosis Study Status Closed to Follow Up
P1004s: Intensive PK substudies in ACTG 403 DAIDS Number 10313 Research Area Other Study Status Concluded
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded